Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial

Key Points

The fixed-dose regimen effectively maintains virologic suppression in HIV-1 patients after 48 weeks.
Participants showed comparable viral load levels, with 82% remaining virologically suppressed at week 48.
Randomized controlled trial evaluating the non-inferiority of the new treatment against standard therapy.
Findings support the potential for a simpler treatment regimen with improved adherence in HIV care.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Phase 3 trial compares fixed-dose regimen to existing therapy in virologically suppressed adults, suggesting efficacy.

No takes yet. Share an insight, caveat, or question.

Colson et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share